Vemlidy
Payments companies reported to CMS as associated with Vemlidy. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Vemlidy, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Vemlidy
These are the largest totals companies reported as associated with Vemlidy. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Douglas Dieterich | New York, NY | Hepatology | $70,641.99 |
| Robert Gish | Folsom, CA | Hepatology | $70,009.94 |
| Sammy Saab | Los Angeles, CA | Gastroenterology (Internal Medicine) | $53,004.54 |
| James Lewis | Washington, DC | Gastroenterology (Internal Medicine) | $51,583.52 |
| Naoky Tsai | Kailua, HI | Gastroenterology (Internal Medicine) | $45,959.86 |
| Francis Yao | San Francisco, CA | Gastroenterology (Internal Medicine) | $45,378.58 |
| Danny Chu | New York, NY | Gastroenterology (Internal Medicine) | $39,807.87 |
| Steven Flamm | Chicago, IL | Gastroenterology (Internal Medicine) | $38,528.41 |
| Enrique Martinez | Atlanta, GA | Hepatology | $37,436.84 |
| Long Nguyen | Lawrenceville, GA | Gastroenterology (Internal Medicine) | $37,289.47 |
Prescribed Vemlidy?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.